Problems with the thyroid – the “gas pedal of the body”, as Dr. Teitelbaum calls it – seem to make sense given the fatigue, exercise and other problems found in ME/CFS and FM. Assessing and treating the thyroid, though, is one area where the practices of chronic fatigue syndrome (ME/CFS) and fibromyalgia (FM) doctors may distinctly diverge from other doctors.
Standard thyroid tests are often negative in ME/CFS and FM but Dr. Bateman has stated that about a third of her ME/CFS patients are hypothyroid. Dr Holtorf – who has published on thyroid issues – believes the standard TSH tests are looking in the wrong place.
Those tests assess the pituitary’s role in triggering thyroid hormone production. Holtorf asserts, though, that pituitary thyroid hormone levels often do not reflect the profound thyroid hormone reductions in other parts of the body in many people with ME/CFS and FM.
T4 – the hormone produced by the thyroid – is not the most active form of thyroid hormone. It’s only when T4 is broken down by non-thyroid tissues, such as the liver, that T3 – the biologically active form of thyroid hormone – is produced.
Holtorf believes that thyroid tests that more directly measure thyroid levels (free T3) or thyroid hormone inhibitors (reverse T3; free T3/reverse T3) as well as other metabolic and inflammatory tests (basal metabolic rate, SHBG, leptin, ferritin, tendon reflexes) should be incorporated into standard ME/CFS and FM testing.
Last year, a large (n=197) Dutch study explored the thyroid question in ME/CFS in greater depth than ever before, and in doing so, may have uncovered a new thyroid illness subset.
Higher Prevalence of “Low T3 Syndrome” in Patients With Chronic Fatigue Syndrome: A Case–Control Study Begoña Ruiz-Núñez1,2*, Rabab Tarasse1, Emar F. Vogelaar3, D. A. Janneke Dijck-Brouwer1 and Frits A. J. Muskiet1. Front. Endocrinol., 20 March 2018 | https://doi.org/10.3389/fendo.2018.00097
Hypothesizing that the “subclinical hypothyroidism” (based on normal TSH levels) found in ME/CFS is caused by low-grade inflammation, these researchers dug deeper than most. Not only did they examine a full array of thyroid measures, but they also assessed traditional markers of inflammation, metabolic inflammation (insulin resistance-mediated, de novo lipogenesis (DNL), and HDL-cholesterol (HDL-C). (Metabolic inflammation refers to conditions where metabolic and inflammatory pathways contribute to atherosclerosis, insulin resistance (IR) and type 2 diabetes.)
Plus, thinking of the leaky gut/inflammation question, they assessed gut wall integrity and the status of nutrients that can influence thyroid function (iodine and selenium) and inflammation (fish oil fatty acids, Vit. D, kyrnurenine, tryptophan, etc.).
With 99 people with ME/CFS and 98 healthy controls, the study appeared quite robust.
The results bore Dr. Holtorf’s conclusions out that TSH tests are insufficient to assess thyroid functioning in chronic fatigue syndrome and fibromyalgia.
These Dutch and Spanish researchers found that TSH levels were indeed similar between ME/CFS patients and healthy controls, but virtually every other thyroid measure was significantly lower in the ME/CFS group (free triiodothyronine (FT3) (difference of medians 0.1%), total thyroxine (TT4) (11.9%), total triiodothyronine (TT3) (12.5%), %TT3 (4.7%), sum activity of deiodinases (14.4%), secretory capacity of the thyroid gland (14.9%), and 24-h urinary iodine (27.6%). Plus, higher percentages of reverse T3 (rT3) (13.3%) suggested that increased levels of thyroid inhibition may be present in ME/CFS.
The authors called the lowered 24-h urine iodine output of ME/CFS patients “remarkable” (which may simply mean “notable”). Both the ME/CFS group and the healthy controls also had about half the optimum omega-3 indexes believed needed to protect against cardiovascular and neuropsychiatric diseases.
Documenting evidence of widespread thyroid problems not picked up by standard TSH tests was progress indeed, but the finding that really stood out concerned the 16% of ME/CFS patients who fit the criteria for “low T3 syndrome”. (Seven percent of the healthy controls did too.)
A New Thyroid Subset for ME/CFS?
Low T3 syndrome or nonthyroidal illness syndrome (NTIS) (or euthyroid sick syndrome ESS) is a debated illness found in some serious illness states including sepsis, starvation, surgery, heart attack, and others. Dr. Leslie J DeGroot, M.D., a top endocrinologist, reported in a 2015 review “The Non-Thyroidal Illness Syndrome” that this syndrome probably occurs in “any severe illness”.
DeGroot starts off his review stating that NTIS, “refers to a syndrome found in seriously ill or starving patients” who have low free T3, increased reverse T3, normal or low TSH, and, if the condition becomes chronic, low free T4. DeGroot asserts that these findings indicate, as Dr. Holtorf asserts, that low tissue thyroid hormone levels are present, and thus tissue hypothyroidism is present. (Note that low total T4 was not found in the ME/CFS group.)
In some ways, this syndrome is no surprise: serum thyroid hormone levels are known to drop during starvation and illness. Starvation (carbohydrate deprivation) inhibits the conversion of T4 to T3 (the active form of thyroid hormone) and prevents the metabolism of reverse T3 (which blocks the receptors for T3, thus reducing the production of T3.)
The reduction of active thyroid hormone levels seems to make sense, given a similar reduction in the basal metabolic rate induced by starvation: the body appears to be hunkering down and attempting to conserve its resources until food is present.
Starvation isn’t the only inducer of this process, though. DeGroot reports that a large proportion of people in intensive care also exhibit low T3 and T4 levels. They also tend to have increased sympathetic nervous system response – which is, of course, typical in ME/CFS.
Various hypotheses have been put forward which propose that NTIS is beneficial or inconsequential and should not be messed with. They include the possibilities that the abnormalities are artifacts, that they do not reflect true free hormone findings, and that they reflect the body’s way of dealing with the situation.
DeGroot, however, believes the findings reflect a pathological state. He does not appear to believe that pituitary thyroid hormone levels differ from those of the body in NTIS, but suggests that cortisol / cytokine levels / low O2 levels (hypoxia) / reduced leptin, etc. are likely responsible for the initiation of NTIS.
The T4 Paradox – When Treatments Make Things Worse
DeGroot’s personal experience is that treating patients with NTIS with T4 (unpublished) often results in significantly elevated rT3 levels (and T3 inhibition).
Nunez-Ruiz et. al. also suggest that standard thyroid therapy (T4) in the NTIS-like ME/CFS subset could actually induce a state of NTIS, and point out that T3, recommended by Holtorf for ME/CFS and FM, has been suggested for severe NTIS. They referred to the NHANES cohort, which found that T4 administration resulted in higher T4 levels but 5–10% lower T3 and FT3 levels, and a 15–20% lower T3/T4 ratio. They believe tissue levels of those factors are probably far lower.
Low “T3 syndrome” in our study resembles the thyroid hormone profile of a subgroup of hypothyroid patients receiving T4 monotherapy. The authors
Holtorf also has found T4 supplementation unproductive and even harmful at times in his ME/CFS and fibromyalgia population. When high levels of rT3 (>150) are found, or free T3/reverse T3 ratio is greater than 0.2 (measured in picograms per milliliter (pg/mL), instead of T4 (Synthroid and Levoxyl or Amour thyroid – a pig glandular product) Holtorf will prescribe free T3 (compounded) instead.
The Worm (Dauer) Rides Again
Ruiz-Nunez et. al. believe the metabolomic studies in ME/CFS may be providing a clue. The impaired mitochondrial production and hypometabolic state they suggest appears to fit with their findings of NTIS in a subset of ME/CFS patients (and one would think the general state of reduced thyroid activity in the group as a whole). Hypothyroidism is, after all, associated with decreases in metabolic and heart rates, oxygen consumption, body temperature and oxidation of glucose, fatty acids, and amino acids.
They throw the whole kit and kaboodle into the mix (inflammation, infection, gut issues, psychological trauma (particularly during childhood) as they suggest that the cell danger response (aka Naviaux) could be behind the NTIS-like findings in some ME/CFS patients. Inflammation may or may not be the issue.
The authors believe that ME/CFS probably represents a common pathophysiological state that can be reached in any number of ways. In a refreshingly direct manner, they reported that their study findings presented one possible way of reaching that state, “but do not get us closer to the cause(s).”
Herpesviruses to the Fore?
Could one answer – HHV-6 – be hiding in plain sight?
Back in 2001, Wikiland reported in The Lancet that fine needle biopsies demonstrated that 40% of people with ME/CFS have lymphocytic thyroiditis. The fact that half of those found with diseased thyroid tissues had normal thyroid lab values suggests that lab values, as Holtorf believes, may not always tell the whole story.
Hashimoto’s thyroiditis, the most common cause of hypothyroidism, occurs as a result of an autoimmune attack. Casselli’s 2012 study finding of a high incidence of HHV-6A DNA in Hashimoto’s thyroid tissues but not in controls (82% vs. 10%, p≤0.001), suggests that HHV-6 could be triggering Hashimoto’s. (HHV-6A was also active in the Hashimoto’s patients, but not in the healthy controls.) If HHV-6A is triggering Hashimoto’s, it might also be triggering the hypothyroidism that seems almost endemic in ME/CFS.
The fact that Caselli found HHV – 6A, not HHV- 6B was notable because while virtually everyone is infected with HHV-6B early in life not everyone is infected with HHV-6A – and when they are it tends to be later in life, which is when most cases of ME/CFS begin.
Kristin Loomis of the HHV-6 Foundation has tried for years to interest someone in examining the thyroid tissue of people with ME/CFS for pathogens. She’s noted that many of the suspected viral culprits in ME/CFS (HHV-6, parvovirus B19) can cause “smoldering” infections in the thyroid.
Now enter Bhupesh Prusty, a Solve ME/CFS Initiative-funded researcher who found HHV-6 in about 60% of a small group of ME/CFS patients’ cells. Prusty found that one HHV-6 infected ME/CFS cell was able to alter the mitochondrial functioning of neighboring, or even distant cells – apparently by secreting mitochondrial inhibitors. Prusty will be speaking at the NIH ME/CFS conference in April.
Kristin Loomis speculates that if HHV-6 is present in the thyroid, it may have found its way to the brainstem as well, where it could help produce the autonomic problems in ME/CFS. At the 2016 IACFS/ME Conference, Dr. Klimas presented evidence that indices of HHV-6 activation are correlated with symptom severity in ME/CFS. Learn more about HHV-6 here.
A fairly large Dutch study found evidence of low thyroid functioning in ME/CFS. The study needs to be replicated, but about 15% of the ME/CFS group met the criteria for Non-Thyroidal Illness Syndrome (NTIS) which occurs in starvation, sepsis and probably other serious illnesses. While most people with ME/CFS did not meet the criteria for NTIS, the overall findings – normal TSH levels, increased reverse T3, and reductions in a variety of thyroid tests – suggest the group as a whole trended in the direction of NTIS.
The findings may call for the use of T3 instead of T4 for some people with ME/CFS/FM. While studies assessing the effectiveness of T3 are lacking, both Leslie DeGroot, a prominent endocrinologist, and Dr. Kent Holtorf, an ME/CFS/FM specialist, support using T3 (in Dr. Holtorf’s case, compounded T3) instead of the usual T4 preparation (such as Synthroid) in patients with NTIS (DeGroot) or ME/CFS/FM (Holtorf).
Learn more about what some doctors say about using T3 in ME/CFS/FM:
The cause of atypical thyroid issues (normal TSH/low T3/high rT3) found in some people with ME/CFS/FM is unknown but could reflect an attempt by the body to conserve resources (Dauer state), could be produced by cytokines, cortisol, hypoxia, etc.) or possibly a pathogen such as HHV-6.
Check out Dr. Holtorf’s approach to ME/CFS and his thyroid testing regiment:
The Low T3 Series on Health RIsing
- The Atypical Thyroid Issues in Chronic Fatigue Syndrome (ME/CFS), Plus a New Thyroid Subset?
- Pure T3 Thyroid and Stories of Recovery from Chronic Fatigue Syndrome (ME/CFS) and Fibromyalgia: An Overview.
Check out the Critical Illness Series as Well
- Neither dying, nor recovering”: Learning from ICUs to Solve ME/CFS and Fibromyalgia – A Synopsis (Nov. 2019)
- Neuroendocrine Dysfunctions in Prolonged Critical Illness: Relevance for Chronic Fatigue Syndrome ME/CFS and Fibromyalgia — Part I: Dysfunctions (Sep. 2019)
- Neuroendocrine Dysfunctions in Prolonged Critical illness: Relevance for Chronic Fatigue Syndrome ME/CFS and Fibromyalgia — Part II: Treatments (Sep. 2019)
- The Relevance of Research on Critical Illnesses for Chronic Fatigue Syndrome ME/CFS: A vicious cycle between cytokines, oxidative stress and thyroid hormones (July 2019)
Support Health Rising in Getting the News Out!
HEALTH RISING IS NOT A 501 (c) 3 NON-PROFIT
After years of work it’s time to attempt what we’ve never been able to do before – get Congress to force the NIH to double its funding for ME/CFS. Support the historic bill to increase research funding, add new ME/CFS research centers, require the development of a strategic plan, etc.. It will take less than 5 minutes.